By flow cytometry, we could then assess separately the proportions and effects of BCG on CD45–EpCAM+ bladder cancer cells and CD45+EpCAM– WBCs from the same tumors (Figure 1B and Supplemental Figure 1). This evidence concerns the gene EPCAM and urinary bladder carcinoma.